



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/698,227
Filing Date	October 31, 2003
First Named Inventor	EHF Wong, et al.
Art Unit	1614
Examiner Name	not available
Attorney Docket Number	00400.US1

Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)

- | | | |
|--|---|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | A return-receipt postcard is enclosed. |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application | Remarks | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Pharmacia & Upjohn Company, Mary J. Hosley (48,324)
Signature	<i>Mary J. Hosley</i>
Date	1 April 2004


CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Julie K. Lyons		
Signature	<i>Julie K Lyons</i>	Date	4/1/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FREE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)**180.00**

Complete if Known

Application Number	10/698,227
Filing Date	October 31, 2003
First Named Inventor	DW Piotrowski, et al.
Examiner Name	
Art Unit	1614
Attorney Docket No.	00400.US1

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number	21-0718
Deposit Account Name	Pharmacia & Upjohn Company

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)			(\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** = 0	X \$0.00	= \$0.00
Multiple Dependent	-3** = 0	X \$0.00	= \$0.00
		\$0.00	= \$0.00

<u>Large Entity</u>		<u>Small Entity</u>		<u>Fee Description</u>
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180.00
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	
Other fee (specify)			
*Reduced by Basic Filing Fee Paid			
SUBTOTAL (3)			(\$) 180.00


SUBMITTED BY		(Complete if applicable)	
Name (Print/Type)	Mary J. Hosley	Registration No. (Attorney/Agent)	48,324
Signature	<i>Mary J. Hosley</i>	Telephone	(269) 833-0975
		Date	1 April 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

04/01/2004 5:11PM 10698227 100.00 DA

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>				Atty. Docket No. 00400.US1		Serial No. 10/698,227	
				Applicant EHF Wong, et. al.			
				Filing Date 10/31/03		Group 1614	
U.S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate	
	AA	6,441,049	27 Aug 2002	ABReitz, et al	514	657	
	AB	2002-0016334	7 Feb 2002	JWCoe, et al	514	303	
	AC	6,054,464	25 Apr 2000	John Macor, et al	514	299	
	AD	5,998,429	7 Dec 1999	Macor et al	514	299	
	AE	5,977,144	2 Nov 1999	Edwin Meyer, et al	514	334	
	AF	5,750,536	12 May 1998	Marco Mantovanini, et al	514	300	
	AG	5,599,937	4 Feb 1997	Gunilla Glas, et al	546	133	
	AH	5,561,149	1 Oct 1996	Moise Azria, et al	514	397	
	AI	5,556,851	17 Sept 1996	Akira Maruyama et al	514	214	
	AJ	5,543,426	6 Aug 1996	A. K. Dixon, et al	514	410	
	AK	5,510,478	23 Apr 1996	Annmarie L. Sabb	540	585	
	AL	5,434,161	18 Jul 1995	Daniel P. Becker	514	300	
	AM	5,362,740	8 Nov 1994	Bedeshi et al.	514	299	
	AN	5,362,734	8 Nov 1994	Terrence J. Ward, et al	514	294	
	AO	5,352,685	4 Oct 1994	Maruyama et al.	514	301	
	AP	5,342,845	30 Aug 1994	Chokal et al.	514	305	
	AQ	5,322,951	21 June 1994	King et al.	548	312	
	AR	5,300,512	5 Apr 1994	Flynn et al	514	305	
	AS	5,273,972	28 Dec 1993	Jagdmann et al	514	210	
	AT	5,272,154	21 Dec 1993	Dixon et al.	514	299	
	AU	5,260,303	9 Nov 1993	Daniel P. Becker, et al	514	300	
	AV	5,246,942	21 Sept 1993	Youssefyeh et al	514	305	
	AW	5,217,975	8 June 1993	Wadsworth et al	514	299	
	AX	5,183,822	2 Feb 1993	Van Wijngaarden et al	514	305	
	AY	5,175,173	29 Dec 1992	Sun	514	305	
	AZ	5,114,947	19 May 1992	Imondi	514	282	
	BA	5,063,231	5 Nov 1991	Sanger et al	512	214	
	BB	5,049,556	17 Sep 1991	King et al	514	183	
	BC	5,039,680	13 Aug 1991	Imperato et al	514	304	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				Atty. Docket No. 00400.US1		Serial No. 10/698,227	
				Applicant EHF Wong, et. al.			
				Filing Date 10/31/03		Group 1614	
	BD	5,001,133	15 Jan 1991	Richardson et al	514	304	
	BE	4,985,437	15 Jan 1991	Tyers	514	304	
	BF	4,983,600	8 Jan 1991	Ward et al	514	214	
	BG	4,973,594	17 Nov 1990	Tyers	514	299	
	BH	4,937,247	26 June 1990	King	514	299	
	BI	4,935,511	19 June 1990	Youssefyeh et al	540	552	
	BJ	4,933,445	12 June 1990	Pelletier et al	540	552	
	BK	4,924,010	8 May 1990	Youssefyeh et al	549	355	
	BL	4,921,982	1 May 1990	Cohen et al	549	462	
	BM	4,920,227	24 Apr 1990	Pelletier et al	546	133	
	BN	4,920,219	14 Apr 1990	Pelletier et al	540	523	
	BO	4,920,127	24 Apr 1990	King	514	278	
	BP	4,910,193	20 Mar 1990	Buchheit	514	216	
	BQ	4,888,353	19 Dec 1989	Lednicer et al	514	422	
	BR	4,882,327	21 Nov 1989	King	514	214	
	BS	4,863,921	5 Sep 1989	Youssefyeh et al	514	230	
	BT	4,863,919	5 Sep 1989	Smith	514	214	
	BU	4,845,092	4 Jul 1989	GJ Sanger et al	514	216	
	BV	4,835,162	30 May 1989	Abood	514	305	
	BW	4,822,795	18 Apr 1989	King	514	214	
	BX	4,803,199	7 Feb 1989	Donatsch et al	514	214	
	BY	4,798,829	17 Jan 1989	King et al	514	214	
	BZ	4,797,406	10 Jan 1989	Richardson et al	514	299	
	CA	4,721,720	26 Jan 1988	Wootton et al	514	304	
	CB	4,612,319	16 Sep 1986	King	514	305	
	CC	4,605,652	12 August 1986	William J. Welstead, Jr	514	214	
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
	CD	WO03/055878A1	10 July 2003	PCT	C07D	453/02	See Eng. Language abstract
	CE	WO 02/100858	19 Dec 2002	PCT	C07D	453/02	

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>				Atty. Docket No. 00400.US1		Serial No. 10/698,227		
				Applicant EHF Wong, et. al.				
				Filing Date 10/31/03		Group 1614		
	CF	WO 02/085901	31 Oct 2002	PCT	C07D	453/02		
	CG	WO 01/76576 A2	18 Oct 2001	PCT	A61K	31/00		
	CH	WO 01/60821 A1	23 Aug 2001	PCT	C07D	453/02		
	CI	WO 01/36417 A1	25 May 2001	PCT	C07D	451/04		
	CJ	WO 01/29034	1 Dec 2000	PCT	C07D	453/02		
	CK	WO 00/73431 A2	7 Dec 2000	PCT	C12N	15/00		
	CL	WO 99/20633	29 Apr 1999	PCT	C07D	519/00	See Eng. Language abstract	
	CM	WO 98/54181	3 Dec 1998	PCT	C07D	451/02		
	CN	WO 97/35860	2 Oct 1997	PCT	C07D	451/14	See Eng. Language abstract	
	CO	WO 96/33186	24 Oct 1996	PCT	C07D	307/79		
	CP	WO 95/27490	19 Oct 1995	PCT	A61K	31/445		
	CQ	WO 95/04742	16 Feb 1995	PCT	C07D	519/00		
	CR	WO 93/09116	13 May 1993	PCT	C07D	453/02	See Eng. language abstract	
	CS	WO 93/06108	1 Apr 1993	PCT	C07D	498/04		
	CT	WO 92/10494	25 Jun 1992	PCT	C07D	451/00		
	CU	WO 91/17161	14 Nov 1991	PCT	C07D	451/14		
	CV	WO 91/09593	20 Dec 1990	PCT	A61K	31/00		
	CW	WO 90/14347	29 Nov 1990	PCT	C07D	453/02		
	CX	EP 0635508	25 Jan 1995	Europe	C07D	495/04		
	CY	EP 0 512 350 A2	11 Nov 1992	Europe	C07D	453/02	X	
	CZ	EP0496064 A1	29 Jul 1992	Europe	C07D	405/12		
	DA	EP 0485962A2	20 May 1992	Europe	C07D	519/00		
	DB	EP0483 836A1	6 May 1992	Europe	C07D	519/00		
	DC	EP0457243A1	21 Nov 1991	Europe	C07D	451/04		
	DE	EP0322016A1	28 Jun 1989	Europe	C07D	519/00		
	DF	EP 0030254B1	12 Jun 1981	Europe	C07D	471/04		
	DG	DE3810552A1	29 March 1988	Germany	C07D	451/12	X	
	DH	JP200230084 [abstract]	12 August 2003	Japan	C08F	279/02		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)								

DI

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No.	Serial No.
		00400.US1	10/698,227
		Applicant EHF Wong, et. al.	
		Filing Date 10/31/03	Group 1614
	DJ	Bencherif, M., <i>Journal of Pharmacology and Experimental Therapeutics</i> , 03(1998) 886-896.	
	DK	Cooper and Millar, <i>J. Neurochem</i> , 1997, 68(5), pp. 2140-51	
	DL	Eisele et al., <i>Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities</i> , <i>Nature</i> , 366(6454), pp. 479-83, 1993	
	DM	Hansen, et al, <i>Bioorg. & Med. Chem. Lett</i> 4 (1994) 695-698	
	DN	Holladay, et al, <i>Journal of Medicinal Chemistry</i> , Vol. 40, Number 26 , 4169-4194, XP-002124847	
	DO	W.R. Kem, <i>The brain $\alpha 7$ nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21)</i> , <i>Behavioural Brain Research</i> 113 (2000) pp. 169-181	
	DP	J.E.Macor, et al, <i>The 5-HT Antagonist Tropiestron (ICS 205-930) is a Potent and Selective $\alpha 7$ Nicotinic Receptor Partial Agonist</i> , <i>Biorganic & Medicinal Chemistry Letters</i> 11 (2001). Pp 319-321	
	DQ	A Orjales, et. al., <i>Benzimidazole-2-carboxylic acid amides and esters: a new structural class of 5-HT₃ ligands</i> , <i>Eur. J. Med. Chem.</i> 34(1999) pp. 415-422.	
	DR	Sabb, et al, <i>Bioorg. & Med. Chem. Lett</i> 9 (1999) 1895-1900	
Examiner		Date Considered	